CESS Cells

The CESS cell line is a B lymphoblastoid cell line derived from a human patient with leukemia. This cell line is commonly used to study immunoglobulin production, particularly IgG secretion, due to its strong response to cytokine stimulation. CESS cells are EBV-transformed and exhibit surface markers characteristic of mature B cells, such as CD19 and CD38. They express the sIgG1 class of immunoglobulins and serve as a model for studying B cell differentiation and function, including immune responses regulated by cytokines like interleukin-6 (IL-6), also known as B-cell stimulation factor 2 (BSF-2). IL-6 plays a crucial role in stimulating immunoglobulin production in CESS cells, making them a valuable model for investigating B cell responses in immunological research. Additionally, CESS cells have been instrumental in studies focusing on cell signaling and apoptosis. Notably, these cells have been shown to produce and respond to Nerve Growth Factor (NGF) through an autocrine signaling mechanism, expressing both high- and low-affinity NGF receptors. Blocking NGF signaling with antibodies or specific inhibitors induces apoptosis in CESS cells, characterized by Bcl-2 phosphorylation and activation of the p38 MAPK pathway. This makes CESS cells an important model for understanding the molecular mechanisms of B cell survival and apoptosis, particularly in the context of NGF signaling and its regulation of the Bcl-2 family proteins. Leukemia cell lines, Peripheral blood, Acute myeloid leukemia, Growth Conditions: Suspension, Biosafety level: BSL 1